Sorafenib-triggered radiation recall dermatitis with a disseminated exanthematous reaction
Radiation Oncology Journal
; : 171-174, 2013.
Article
de En
| WPRIM
| ID: wpr-116460
Bibliothèque responsable:
WPRO
ABSTRACT
Sorafenib is a multi-targeted kinase inhibitor, which is the current standard treatment for advanced hepatocellular carcinoma (HCC). Only one case of radiation recall dermatitis (RRD) associated with sorafenib has been reported so far. Our patient with recurrent HCC was treated with palliative radiotherapy (RT) for the chest wall mass. Sorafenib at 400 mg twice daily was begun on the day following RT. On the 14th day post-RT, an erythematous patch was observed on right chest wall which matched area previously irradiated. It was consistent with RRD. Ten days later, a disseminated exanthematous rash and severe pruritus occurred. Sorafenib was stopped and an oral antihistamine was prescribed to relieve symptoms. At the 1-week follow-up after the cessation of sorafenib, all symptoms were resolved. Physicians should be alert to this recall phenomenon as it can occur both in the skin and elsewhere and the occurrence of RRD may be unpredictable.
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Phénylurées
/
Phosphotransferases
/
Prurit
/
Radiodermite
/
Peau
/
Études de suivi
/
Nicotinamide
/
Carcinome hépatocellulaire
/
Paroi thoracique
/
Exanthème
Type d'étude:
Observational_studies
/
Prognostic_studies
Limites du sujet:
Humans
langue:
En
Texte intégral:
Radiation Oncology Journal
Année:
2013
Type:
Article